Partnership13 Feb 2026, 11:08 am
Shilpa Medicare Enters Strategic Partnership with NXI Therapeutics AG for Novel Asset Targeting Autoimmune and Alloimmune Disorders
AI Summary
Shilpa Medicare Limited has entered into a binding agreement with NXI Therapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. This is the third major international mandate in recent months for Shilpa Medicare, reinforcing accelerating biotech traction and long-term revenue visibility. The partnership spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program. The agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progression.
Key Highlights
- Shilpa Medicare Limited has entered into a strategic partnership with NXI Therapeutics AG for a novel therapy targeting autoimmune and alloimmune disorders.
- The partnership spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program.
- The agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship.
- This is the third major international development and manufacturing contract secured by Shilpa group, underscoring strengthening demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure.
- The autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies.